Claims of diabetes medications used as “easy #weightloss solutions” have sparked discussions online and in the media. But there is much more to the debate. ❓ What are GLP-1 receptor agonists? 💊How do they work? 🍏 What is their impact on people living with obesity? On 22 July, we interviewed Bart Van der Schueren (European Medicines Agency expert and obesity specialist) to discover more about these medicines and their impact. 📺👨⚕️ Watch the full interview: on YouTube: https://lnkd.in/dVMuWcXV or on the Instagram channel @one_healthenv_eu
European Medicines Agency
Overheidsinstanties
Amsterdam, North Holland 307.572 volgers
The mission of EMA is to foster scientific excellence in the evaluation and supervision of medicines in the EU.
Over ons
The European Medicines Agency (EMA) is a decentralised body of the European Union with headquarters in Amsterdam. Its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use.
- Website
-
http://www.ema.europa.eu
Externe link voor European Medicines Agency
- Branche
- Overheidsinstanties
- Bedrijfsgrootte
- 501 - 1.000 medewerkers
- Hoofdkantoor
- Amsterdam, North Holland
- Type
- Overheidsinstelling
- Opgericht
- 1995
Locaties
-
Primair
Domenico Scarlattilaan 6
Amsterdam, North Holland 1083, NL
Medewerkers van European Medicines Agency
Updates
-
Join our workshop to learn about the importance of pharmacogenomics in health and medicine regulation and explore how it can guide personalised treatments. You'll have the chance to: ✔explore how genomic data can improve healthcare for European patients; ✔learn how pharmacogenomic data can guide treatment decisions and contribute to the safety of medicines; ✔discuss how to promote the integration of pharmacogenomics in clinical practice. The workshop is organised by EMA, the European Commission and the Heads of Medicines Agencies. 🗓️ 24 September 2024, 09:00–17:00 (CEST) 🔔 Register for virtual participation by 13 September 2024 💻 No need to register to follow the live broadcast 🔗 More information: https://lnkd.in/dBafqeJR
-
-
📢 Calling on all marketing authorisation applicants. The EU regulatory network’s resource planning is affected by: ➡️ frequent changes in agreed submission dates of initial marketing applications for centralised procedures ➡️ unpredictability of post-marketing submissions. This uncertainty can put the system under pressure. A Joint EMA-HMA workshop will focus on improving the predictability of submission for marketing authorisations applications. Representatives from the national competent authorities, industry, and EMA will get together looking for solutions, share best practices and improve cooperation. Big, medium, small pharmaceutical industry, CROs and academia – come be part of this conversation! 🗓️ 25 September 2024, 09:00 - 13:30 Amsterdam time (CET) 💻 Online – live broadcast 🔗 https://lnkd.in/gaChRZ8V
-
-
🤔 ❓ Have you ever wondered how medicines are named? EMA plays a crucial role in approving the names of all medicines in the EU. The naming process ensures that the names given to the medicines are: 🚫 Not promotional 🚫 Not easily confused with other pharmaceutical products 🚫 Not misleading Clear and accurate naming is crucial for patient safety and effective healthcare delivery. Watch this video to find out! 📹 #Medicines #OneHealthEU #PublicHealth #EU #EMA
-
📅 SME Survey 2024: deadline extended! We invite #SMEs and industry stakeholders to share their insights on the support, services, and incentives EMA provides. The survey is open until 16 September. Results will be shared anonymously in 2025, followed by a comprehensive report on the key findings. 👉 Make your voice heard and contribute to the future of SME support at EMA: https://lnkd.in/ecpbuDmP
📢 Exciting opportunity for SMEs: Your Voice Matters! EMA's SME office has launched a survey to gather feedback from small and medium-sized enterprises (SMEs) and industry stakeholders. 🏢💬 Your insights are crucial in helping EMA understand current challenges and better tailor future activities to the needs of SMEs 🗓 Deadline: 12 July 📝 Survey link: https://lnkd.in/ecpbuDmP Let's work together to create a more supportive environment for SMEs. 🚀
-
-
🦟🚨 Mosquito-borne diseases are an increasing risk in the EU. 📈 It's crucial to stay informed and take preventive measures to protect yourself. 💉 To find out more about vaccines authorised in the EU against certain potentially fatal mosquito-borne diseases, check out our carousel. Stay safe and help spread awareness, share this post! 🦟🛡️ #PublicHealth #Dengue #Malaria #YellowFever #Chikungunya #Zika #StaySafe #Mosquito #EMA #Health #ClimateChange
-
On 2 July, we had the pleasure of welcoming Dr Drew Weissman, the 2023 winner of the Nobel Prize in Physiology or Medicine, as a guest speaker at the European Medicines Agency. Drew Weissman is the Roberts Family Professor in Vaccine Research and director of the Penn Institute for RNA Innovation in Medicine at the Perelman School of Medicine. He is recognised for his contributions with Katalin Karikó to the development of the mRNA technology, which laid the foundation for effective mRNA vaccines against #COVID19 during the pandemic. Dr Weissman’s current research focuses on developing a vaccine to stop the next coronavirus epidemic, a universal flu vaccine and the development of cancer therapeutics with #mRNA technology. Dr Weissman had an inspiring discussion with Emer Cooke, our Executive Director, on topics such as: ✔️The potential of RNA technology to treat allergies or diseases affecting the heart, as well as its application in fields like gene editing and CAR-T cell therapy; ✔️Strategies to achieve greater #equity in access to vaccines and therapeutics; ✔️Tackling #vaccinehesitancy and false narratives about science; ✔️The importance of creativity and curiosity in the field of research. Watch the full recording here!
Share Science, Achieve Breakthroughs: A Conversation with Nobel Laureate Dr. Drew Weissman
https://www.youtube.com/
-
A high demand for #GLP-1 receptor agonists has led to shortages across the EU of medicines that have been hailed as easy “#weightloss drugs” 📉💊 In June, EMA published recommendations to all stakeholders to help tackle these shortages, since we can all help to protect those who need them. Doctors have an important role. What are they thinking when they’re prescribing these treatments? Who can they help most and who are we looking out for during these shortages? 💪 Watch the full interview with Dr. Bart Van der Schueren, an European Medicines Agency expert and obesity specialist, to find out more. 📺 Available on YouTube: https://lnkd.in/dVMuWcXV or on the Instagram channel @one_healthenv_eu
-
📢 Exciting News: We have 10 traineeship opportunities starting in March 2025! Are you interested in one of these fields? Apply by 30 September 2024 and take the next step in your career journey! 🌟 🔹 Scientific Evidence Generation: Cooperation between regulators and HTA 🔹 Stakeholder engagement 🔹 Translational sciences: Implementing the '3Rs' in medicines development and regulation 🔹 Data Scientist in the Analytics Centre of Excellence 🔹 Information Centre: Library 🔹 Change Management Centre of Expertise 🔹 Data Management 🔹 Software and Cloud engineer 🔹 Verification of accounting records 🔹 Monitoring of antimicrobial consumption and resistance Read more here: 🔗 https://lnkd.in/ehCPw3J #Traineeship #CareerOpportunities #Pharma #JobInPharma #EUjobs #EMAjobs
-
-
Did you miss the insightful LinkedIn live discussion on the therapeutic potential of psychedelics in mental health 🧠 between EMA’s Chief Medical Officer, Steffen Thirstrup, and our press officer, Alessandro Faia? Watch now the recording of this live session: https://lnkd.in/ehHPTKjw Some of the main take-aways: 📌 Developers should get in touch with regulators as early as possible to ensure their development plans align with existing regulatory frameworks; 📌 We must prioritise reliable and valid evidence to address uncertainties in psychedelic research such as optimal dosing and the requirements for “set and setting”; 📌 Collaboration between regulators, researchers, patients, policymakers, healthcare professionals and industry is crucial to advance innovative treatments for mental health conditions. #MentalHealth #Psychedelics #medicineregulation
EMA LinkedIn Live session on psychedelics and their therapeutic use
https://www.youtube.com/